Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2001 1
2004 1
2005 1
2009 2
2010 1
2011 8
2012 6
2013 3
2014 2
2015 2
2016 4
2017 2
2018 2
2019 2
2020 2
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M. Bagley SJ, et al. Clin Cancer Res. 2022 Feb 15;28(4):594-602. doi: 10.1158/1078-0432.CCR-21-2750. Clin Cancer Res. 2022. PMID: 34561269 Free PMC article. Review.
In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of …
In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and ea …
Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report.
Lu VM, Shah AH, Vallejo FA, Eichberg DG, Luther EM, Shah SS, Komotar RJ, Ivan ME. Lu VM, et al. Neurosurg Focus. 2021 Feb;50(2):E3. doi: 10.3171/2020.11.FOCUS20860. Neurosurg Focus. 2021. PMID: 33524946
OBJECTIVE: Adult glioblastoma (GBM) has proven refractory to decades of innovation. ...Despite the growing body of basic science data supporting the feasibility of viral therapy to treat GBM, the reporting of clinical trial results is heterogeneous. Co …
OBJECTIVE: Adult glioblastoma (GBM) has proven refractory to decades of innovation. ...Despite the growing body of basic scien …
Tumor treating fields in pediatric high-grade glioma.
Green AL, Mulcahy Levy JM, Vibhakar R, Hemenway M, Madden J, Foreman N, Dorris K. Green AL, et al. Childs Nerv Syst. 2017 Jul;33(7):1043-1045. doi: 10.1007/s00381-017-3431-0. Epub 2017 May 3. Childs Nerv Syst. 2017. PMID: 28470383
The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children. METHODS: We report a feasibility case series of five pediatric high-grade glioma patients (ages 10-20 years) treated at our institution with TTF alo …
The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children. METHODS: …
Glioblastoma survival in the United States before and during the temozolomide era.
Johnson DR, O'Neill BP. Johnson DR, et al. J Neurooncol. 2012 Apr;107(2):359-64. doi: 10.1007/s11060-011-0749-4. Epub 2011 Nov 2. J Neurooncol. 2012. PMID: 22045118
It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benefit extends to patients older than those enrolled in the trial. Data from the Surveillance, Epidemiology, and End Results (SEER) Progr …
It is not yet clear how this change in treatment has influenced patient survival in routine clinical practice, or if a survival benef …
Biomarker-based prognostic stratification of young adult glioblastoma.
Zhang RQ, Shi Z, Chen H, Chung NY, Yin Z, Li KK, Chan DT, Poon WS, Wu J, Zhou L, Chan AK, Mao Y, Ng HK. Zhang RQ, et al. Oncotarget. 2016 Jan 26;7(4):5030-41. doi: 10.18632/oncotarget.5456. Oncotarget. 2016. PMID: 26452024 Free PMC article.
In this study, we sought to stratify young adult glioblastomas by BRAF, H3F3A and IDH1 mutations and examine the clinical relevance of the biomarkers. In 107 glioblastomas aged from 17 to 35 years, mutually exclusive BRAF-V600E (15%), H3F3A-K27M (15.9%), H3F3A-G34R/V (2.8% …
In this study, we sought to stratify young adult glioblastomas by BRAF, H3F3A and IDH1 mutations and examine the clinical relevance o …
Angiogenesis as a therapeutic target in malignant gliomas.
Chi AS, Sorensen AG, Jain RK, Batchelor TT. Chi AS, et al. Oncologist. 2009 Jun;14(6):621-36. doi: 10.1634/theoncologist.2008-0272. Epub 2009 Jun 1. Oncologist. 2009. PMID: 19487335 Free PMC article. Review.
Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging eff …
Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highl …
Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.
Gunjur A, Balasubramanian A, Hafeez U, Menon S, Cher L, Parakh S, Gan HK. Gunjur A, et al. J Neurooncol. 2022 Sep;159(3):539-549. doi: 10.1007/s11060-022-04092-7. Epub 2022 Aug 6. J Neurooncol. 2022. PMID: 35933567 Review.
METHODS: We identified phase I trials (P1Ts) of tumor targeted drugs, subsequent trial results and preceding relevant preclinical data published in adult glioblastoma patients between 2006-2019 via structured searches of EMBASE/MEDLINE/PUBMED. ...Twenty-three …
METHODS: We identified phase I trials (P1Ts) of tumor targeted drugs, subsequent trial results and preceding relevant preclinical dat …
Zika virus has oncolytic activity against glioblastoma stem cells.
Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG. Zhu Z, et al. J Exp Med. 2017 Oct 2;214(10):2843-2857. doi: 10.1084/jem.20171093. Epub 2017 Sep 5. J Exp Med. 2017. PMID: 28874392 Free PMC article.
Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients....
Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further opt …
The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C, Wang Q, Yan X, Wang J. Shu C, et al. Cancer Med. 2018 Aug;7(8):3704-3712. doi: 10.1002/cam4.1666. Epub 2018 Jul 9. Cancer Med. 2018. PMID: 29984907 Free PMC article.
METHOD: A total of 304 adult glioblastoma samples collected after surgical resection were selected for retrospective analysis, and Sanger sequencing was performed to detect IDH and TERT promoter mutations. ...RESULTS: Wild-type IDH was present in 89.8% of the adu …
METHOD: A total of 304 adult glioblastoma samples collected after surgical resection were selected for retrospective analysis, …
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Ortega A, Sarmiento JM, Ly D, Nuño M, Mukherjee D, Black KL, Patil CG. Ortega A, et al. J Clin Neurosci. 2016 Feb;24:105-11. doi: 10.1016/j.jocn.2015.05.047. Epub 2015 Dec 5. J Clin Neurosci. 2016. PMID: 26671314
We investigated the relationship between multiple tumor resections and overall survival (OS) in adult glioblastoma patients who received adjuvant radiotherapy and temozolomide following initial surgery. ...
We investigated the relationship between multiple tumor resections and overall survival (OS) in adult glioblastoma patients wh …
36 results